Skip to content

This site uses Google Analytics to see which pages people find useful. Google receives page views, IP-derived approximate location, device and browser type, and the referring site. Privacy details.

All instruments

Sun Pharmaceutical Industries Limited

Formerly Sun Pharmaceuticals Industries Limited

  • Stock
  • SUNPHARMA
  • NSE
  • ₹1,860.00+1.69%
  • Delayed close, 06 Nov
Details
Add to My money

Paid for 22 years without a break

Dividend per share by FY

Split-adjusted · FY 2026–27 to date · last 7 of 22 years · FY of the ex-date
Dividend per share by financial year of the ex-date
Financial yearTotal dividend
FY 2001–02₹0.50
FY 2005–06₹0.38
FY 2006–07₹1.23
FY 2008–09₹1.05
FY 2009–10₹1.38
FY 2010–11₹1.38
FY 2011–12₹1.75
FY 2012–13₹2.13
FY 2013–14₹2.50
FY 2014–15₹1.50
FY 2015–16₹3.00
FY 2016–17₹1.00
FY 2017–18₹3.50
FY 2018–19₹2.00
FY 2019–20₹5.75
FY 2020–21₹6.50
FY 2021–22₹9.00
FY 2022–23₹10.50
FY 2023–24₹12.50
FY 2024–25₹15.50
FY 2025–26₹16.50
FY 2026–27₹5.00

TTM payout

₹16.00

2 payouts in 12 months

Yield

0.86%

Dividend yield · trailing 12 months

52-wk closing range ₹1,589.30 – ₹2,001.10 · split-adjusted

Yield and payout totals recalculated 07 Nov 2026.

Recent payouts

· 30 on record since FY 2001–02
Payout history
Ex-dateRecord dateAmount
07 Jul 2026same day₹5.00
05 Feb 2026same day₹11.00
07 Jul 2025same day₹5.50
06 Feb 2025same day₹10.50
12 Jul 2024same day₹5.00

Amounts marked * were restated for a later split or bonus so they compare with today’s shares. Switch to “as filed” to see what was actually declared at the time — that is the figure on an old broker statement.

Income calculator

₹848

Expected income per year, before tax, at the current 0.86% yield

≈ 53 shares at ₹1,860.00, using ₹98,580 of the ₹1,00,000. Based on the last twelve months’ payouts — not a forecast, and dividends are taxed at your own slab rate.

Similar current yields

Same asset type, ordered by distance from this instrument’s published trailing-12-month yield. These are not business-sector peers or recommendations.